© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
We are privileged to come to work each day
and do something extraordinary.
Laura Clague, CPA, has served as chief financial officer of Travere Therapeutics since November 2014. Ms. Clague has 30 years of experience as a financial executive, and oversees the company’s accounting, finance, IT and facilities functions. Previously, Ms. Clague served as chief financial officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the vice president, corporate controller and principal accounting officer of Amylin for 10 years, when she also served as the chief financial officer of Amylin’s collaboration with Eli Lilly and Company.
Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation and KPMG. Ms. Clague currently serves on the board of directors of Fluidigm Corporation and Genasys, Inc. Ms. Clague is a certified public accountant in the State of California, and received a bachelor’s in business administration from Menlo College.